

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



Corrigendum

Corrigendum to “Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial” [Eur Urol 2022;81(6):598–605]

Taimur T. Shah^{a,b,c,1,*}, Abi Kanthabalan^{c,1}, Marjorie Otieno^c, Menelaos Pavlou^d, Rumana Omar^d, Sola Adeleke^{e,f,g,t,u}, Francesco Giganti^{c,h}, Chris Brew-Graves^e, Norman R. Williams^c, Jack Grierson^c, Haroon Miah^c, Amr Emara^{i,v}, Athar Haroon^{j,k}, Arash Latifoltojar^{e,l}, Harbir Sidhu^{e,h}, Joey Clemente^c, Alex Freeman^m, Clement Orczyk^{c,n}, Ashok Nikapota^o, Tim Dudderidge^p, Richard G. Hindleyⁱ, Jaspal Viridi^q, Mani Arya^b, Heather Payne^r, Anita Mitra^r, Jamshed Bomanji^k, Mathias Winkler^{a,b}, Gail Horan^s, Caroline M. Moore^{c,n}, Mark Emberton^{c,n}, Shonit Punwani^{e,h}, Hashim U. Ahmed^{a,b}

^aImperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; ^bImperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; ^cDivision of Surgery and Interventional Sciences, University College London, London, UK; ^dDepartment of Statistical Science, University College London, London, UK; ^eDivision of Medicine, Faculty of Medicine, University College London, London, UK; ^fDepartment of Oncology, King's College London, London, UK; ^gDepartment of Oncology, Maidstone and Tunbridge Wells Hospital, Maidstone, UK; ^hDepartment of Radiology, University College London Hospital NHS Foundation Trust, London, UK; ⁱDepartment of Urology, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; ^jDepartment of Nuclear Medicine, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK; ^kInstitute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK; ^lDepartment of Radiology, Royal Marsden NHS Foundation Trust, London, UK; ^mDepartment of Histopathology, University College London Hospital NHS Foundation Trust, London, UK; ⁿDepartment of Urology, University College London Hospital NHS Foundation Trust, London, UK; ^oSussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK; ^pDepartment of Urology, University Hospital Southampton NHS Trust, Southampton, UK; ^qDepartment of Urology, The Princess Alexandra Hospital NHS Trust, Harlow, UK; ^rDepartment of Oncology, University College London and University College London Hospital NHS Foundation Trust, London, UK; ^sDepartment of Oncology, Queen Elizabeth Hospital, Kings Lynn, UK; ^tSchool of Cancer & Pharmaceutical Sciences, King's College London, Queen Square, London WC1N 3BG, UK; ^uHigh Dimensional Neurology, Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, University College London, London, UK; ^vUrology Department, Ain Shams University Hospitals, Cairo, Egypt

The authors would like to amend the title of the paper to better reflect the study.

Current title: Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to focal ablation in localised and metastatic recurrent prostate cancer after radiotherapy.

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.02.022>

¹ These authors contributed equally and are joint first authors.

* Corresponding author. Imperial Prostate, Charing Cross Hospital Campus, Imperial College London, Fulham Palace Road, London W6 8RF, UK.
E-mail address: t.shah@imperial.ac.uk (T.T. Shah).

<https://doi.org/10.1016/j.eururo.2023.01.004>

0302-2838/© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article as: T.T. Shah, A. Kanthabalan, M. Otieno et al., Corrigendum to “Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial” [Eur Urol 2022;81(6):598–605], Eur Urol (2023), <https://doi.org/10.1016/j.eururo.2023.01.004>

Amended Title: Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to **salvage focal therapy/ablation** in localised and metastatic recurrent prostate cancer after radiotherapy. **Primary Outcomes from the FORECAST Trial.**

The authors would like to apologise for any inconvenience caused.